종양 영양 시장 : 제품 유형별, 투여 경로별, 암 유형별, 연령층별, 유통 채널별 시장 예측(2026-2032년)

The Oncology Nutrition Market is projected to grow by USD 5.20 billion at a CAGR of 8.22% by 2032.

Oncology nutrition is becoming a core component of cancer care as health systems confront a rising global cancer burden and the clinical consequences of malnutrition, cachexia, sarcopenia, treatment intolerance, and reduced quality of life. The International Agency for Research on Cancer reported nearly 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with cases projected to exceed 35 million by 2050. This expanding patient population is increasing demand for evidence-based nutrition screening, oral nutritional supplements, enteral and parenteral nutrition, immunonutrition, and digitally enabled dietetic support across the cancer care continuum.

The oncology nutrition market is shaped by a strong clinical rationale: cancer-associated malnutrition is reported across tumor types and care settings, with higher prevalence in gastrointestinal, head and neck, lung, pancreatic, and advanced-stage cancers. International clinical guidance, including recommendations from ESPEN and oncology nutrition societies, emphasizes routine nutrition risk screening, early intervention, individualized protein and energy targets, symptom management, and multidisciplinary coordination. As oncology shifts toward precision medicine, cancer nutrition is also moving from supportive care to an integrated strategy that can help preserve functional status, improve treatment completion, and support survivorship outcomes.

Transformative Shifts in the Oncology Nutrition Landscape

The oncology nutrition landscape is being transformed by earlier nutrition screening, greater attention to muscle preservation, and a shift from reactive feeding support to proactive, personalized care. Cancer centers are increasingly embedding registered dietitians into tumor boards, infusion centers, radiation oncology pathways, and survivorship clinics to address nutrition-impact symptoms such as dysphagia, mucositis, nausea, altered taste, anorexia, diarrhea, constipation, and fatigue before they compromise therapy adherence.

Product innovation is also accelerating across high-protein oral nutritional supplements, omega-3-enriched formulas, diabetes-specific formulations, elemental and semi-elemental feeds, and modular protein products designed for complex oncology needs. At the same time, home-based care, remote patient monitoring, and hospital-at-home models are expanding demand for nutrition solutions that are clinically reliable, easy to administer, reimbursable, and compatible with multidisciplinary follow-up. Regulatory expectations around substantiation, safety, labeling, and medical claims remain a defining factor for competitive differentiation.

Cumulative Impact of Artificial Intelligence on Oncology Nutrition

Artificial intelligence is beginning to reshape oncology nutrition through risk stratification, workflow automation, and personalization. AI-enabled tools can analyze electronic health records, laboratory results, weight trends, treatment regimens, patient-reported outcomes, and imaging-derived body composition markers to identify patients at elevated risk of malnutrition or sarcopenia. These applications are especially relevant because weight alone can mask muscle loss in patients with obesity, edema, or fluid retention.

The cumulative impact of AI is expected to be strongest where it supports clinicians rather than replaces them. Predictive analytics can prompt earlier dietitian referrals, flag nutrition-impact toxicities, optimize follow-up intervals, and support adherence monitoring for oral supplements or tube feeding regimens. However, adoption depends on transparent model validation, bias mitigation, data privacy compliance, integration with oncology workflows, and alignment with medical device and clinical decision support regulations. Organizations that combine AI with evidence-based oncology nutrition protocols will be better positioned to demonstrate measurable improvements in patient experience, operational efficiency, and continuity of care.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is a high-potential region for oncology nutrition because it combines a large and aging population, rising cancer incidence, expanding private healthcare, and increasing access to modern oncology services. China, India, Japan, South Korea, and Australia are strengthening cancer screening and treatment infrastructure, while nutrition support is gaining visibility in surgical oncology, chemoradiation, and survivorship. Japan and South Korea show strong clinical adoption of specialized medical nutrition and aging-related care models, while India and Southeast Asia continue to balance rapid demand growth with affordability, awareness, and access constraints.

North America remains one of the most mature oncology nutrition environments due to advanced cancer networks, strong dietitian integration, clinical guideline adoption, patient assistance programs, and broad availability of specialized oral and enteral nutrition products. Europe is similarly guideline-driven, with the European Union emphasizing quality standards, clinical nutrition research, and cross-border regulatory consistency, while the United Kingdom, Germany, France, Italy, and Spain maintain strong institutional oncology care pathways. Latin America, led by Brazil and Mexico, is expanding oncology capacity, but uneven reimbursement and public-sector resource constraints affect access to specialized nutrition. The Middle East, particularly GCC countries, is investing in cancer centers and medical nutrition services, while Africa faces the dual challenge of rising cancer burden and undernutrition, making scalable screening, affordable supplementation, reliable procurement, and workforce development critical.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN presents a diverse oncology nutrition opportunity, with Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines at different stages of oncology infrastructure maturity. Urban private hospitals are adopting specialized nutrition services faster, while public systems need cost-effective products, clinical training, and screening tools that can scale across high-volume settings. GCC countries are advancing through government investment in cancer care, high rates of diabetes and obesity that complicate nutrition planning, and growing demand for premium clinical nutrition in hospital and homecare settings.

The European Union provides a favorable environment for evidence-based oncology nutrition because of harmonized food and medical nutrition regulations, strong clinical nutrition societies, and structured cancer policy initiatives. BRICS countries represent a large-volume opportunity driven by population scale, cancer incidence, local manufacturing potential, and expanding oncology coverage, though affordability and regional disparities remain decisive. G7 markets lead in research intensity, clinical protocol development, reimbursement sophistication, digital health integration, and premium product adoption. NATO countries, while not a healthcare market bloc, are increasingly relevant to supply-chain resilience, medical readiness, and procurement stability for critical nutrition products used in hospitals, emergency care, and complex chronic disease management.

Key Country Insights Across Major Oncology Nutrition Markets

The United States leads in oncology nutrition innovation through comprehensive cancer centers, strong clinical trial activity, digital health adoption, and broad availability of oral, enteral, and parenteral nutrition products, although reimbursement complexity and disparities in dietitian access remain persistent challenges. Canada benefits from universal healthcare structures and cancer agency coordination, while Mexico is expanding oncology services but faces uneven access between public and private systems. Brazil is the largest Latin American opportunity, supported by a sizable cancer population and hospital nutrition demand, while access and funding variability continue to shape adoption of specialized cancer nutrition supplements and enteral nutrition in cancer care.

In Europe, the United Kingdom emphasizes integrated cancer pathways and survivorship support, Germany combines strong hospital infrastructure with clinical nutrition adoption, and France maintains a well-developed oncology system with attention to supportive care. Italy and Spain continue to advance nutrition screening and geriatric oncology practices, while Russia presents a large patient base with regional differences in access and procurement. In Asia-Pacific, China is scaling oncology infrastructure rapidly and building domestic medical nutrition capabilities; India has high demand potential but requires affordability, awareness, and distribution expansion; Japan's aging population supports advanced clinical nutrition integration; Australia benefits from guideline-based supportive care; and South Korea combines high healthcare digitization with sophisticated cancer treatment pathways.

Actionable Recommendations for Oncology Nutrition Industry Leaders

Industry leaders should prioritize clinically validated, oncology-specific nutrition solutions that address protein adequacy, muscle preservation, gastrointestinal tolerance, metabolic complications, and therapy-related symptoms. Organizations that invest in real-world evidence, health economic studies, and outcomes linked to treatment completion, hospital length of stay, readmissions, adverse event management, and patient-reported quality of life will be better positioned with payers, providers, and cancer centers.

Commercial strategy should combine product innovation with service models. This includes dietitian education, nutrition screening tool integration, digital adherence support, multilingual patient resources, and partnerships with oncology networks, homecare providers, and patient advocacy organizations. Leaders should also localize portfolios by region: premium specialized formulas may perform well in mature markets, while affordable high-protein supplements, modular products, and scalable screening programs are essential in emerging markets. Supply-chain resilience, regulatory compliance, clinical substantiation, and ethical AI governance should be treated as strategic priorities rather than back-office functions.

Research Methodology

This executive summary is based on a structured secondary research methodology using publicly available, authoritative sources, including cancer epidemiology from IARC and WHO, clinical nutrition guidance from ESPEN and oncology nutrition organizations, national cancer agencies, peer-reviewed literature, regulatory frameworks, and healthcare policy publications. Market interpretation was developed by triangulating disease burden, nutrition risk evidence, oncology care infrastructure, reimbursement conditions, product adoption patterns, and regional healthcare investment trends.

Insights were evaluated for consistency across multiple data sources and framed to avoid unsupported market sizing or speculative claims. Qualitative assessment included clinical pathway analysis, regional access dynamics, digital health readiness, and the role of multidisciplinary cancer care. The methodology emphasizes data-backed interpretation, practical relevance, and focused clarity for stakeholders evaluating the oncology nutrition market, cancer nutrition supplements, enteral nutrition in cancer care, immunonutrition, oncology dietitian services, and personalized nutrition for oncology patients.

Conclusion

Oncology nutrition is entering a more strategic phase as cancer care becomes more personalized, multidisciplinary, and outcomes-focused. The strongest opportunities will emerge where nutrition is integrated early, measured consistently, and connected to treatment tolerance, functional preservation, and survivorship. Rising cancer incidence, aging populations, and growing recognition of malnutrition, sarcopenia, and cachexia are creating sustained demand for specialized nutrition products and services.

The competitive landscape will reward organizations that combine clinical credibility, patient-centered design, digital enablement, regional affordability, and evidence generation. As AI, homecare, and precision oncology evolve, nutrition will become increasingly important to comprehensive cancer care. Organizations that align innovation with guidelines, reimbursement realities, and equitable access will be best positioned to lead the global oncology nutrition market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oncology Nutrition Market, by Product Type

• 7.1. Enteral Nutrition
  • 7.1.1. Elemental Formulas
  • 7.1.2. Modular Formulas
  • 7.1.3. Standard Formulas
• 7.2. Oral Nutritional Supplements
  • 7.2.1. Disease Specific
  • 7.2.2. High Protein
  • 7.2.3. Immunonutrition
• 7.3. Parenteral Nutrition
  • 7.3.1. Supplemental Parenteral Nutrition
  • 7.3.2. Total Parenteral Nutrition

8. Oncology Nutrition Market, by Route Of Administration

• 8.1. Enteral
• 8.2. Oral
• 8.3. Parenteral

9. Oncology Nutrition Market, by Cancer Type

• 9.1. Breast Cancer
• 9.2. Gastrointestinal Cancer
• 9.3. Head & Neck Cancer
• 9.4. Hematologic Malignancies
• 9.5. Lung Cancer
• 9.6. Gynecologic Cancer

10. Oncology Nutrition Market, by Age Group

• 10.1. Pediatric
• 10.2. Adult
• 10.3. Geriatric

11. Oncology Nutrition Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Retail
• 11.3. Retail Pharmacies
• 11.4. Specialty Clinics

12. Oncology Nutrition Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Oncology Nutrition Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Oncology Nutrition Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. ADM Human Nutrition
• 16.3. Ajinomoto Co., Inc.
• 16.4. Arla Foods Ingredients Group P/S
• 16.5. B. Braun Melsungen AG
• 16.6. Baxter International Inc.
• 16.7. Danone S.A.
• 16.8. Fresenius Kabi AG
• 16.9. Global Health Products, Inc.
• 16.10. Hormel Foods Corporation
• 16.11. Kerry Group plc
• 16.12. Lonza Group AG
• 16.13. Mead Johnson Nutrition Company, LLC
• 16.14. Meiji Holdings Co., Ltd.
• 16.15. Nestle Health Science S.A.
• 16.16. Otsuka Pharmaceutical Co., Ltd.
• 16.17. Perrigo Company plc
• 16.18. Rousselot B.V.
• 16.19. Tate & Lyle plc
• 16.20. Victus, Inc.
• 16.21. Vitaflo International Ltd.
• 16.22. Yakult Honsha Co., Ltd.